Peptide Research Profile

BPC-157

Body Protection Compound 157 — Synthetic Pentadecapeptide

Evidence Grade: Preclinical (No Human RCTs)

A synthetic 15-amino-acid peptide derived from a protective protein found in human gastric juice. Extensively studied in rodent models for wound healing, tendon repair, gastrointestinal protection, and neuroprotection. Despite strong preclinical interest, no completed randomized controlled human trial exists as of 2025.

Medical Disclaimer: This profile is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. The evidence presented is primarily preclinical. Always consult a qualified healthcare professional before using any peptide compound. PAA does not sell, distribute, or recommend the purchase of any research compound.

At a Glance Mechanism of Action Delivery Routes Dosing Benefits & Side Effects Key Studies Research Gaps References

Quick Reference

At a glance

Classification

Pentadecapeptide

15 amino acids, synthetic derivative of BPC (body protection compound) isolated from human gastric juice

Molecular Weight

1,419 Da

Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Primary Routes

SubQ · Oral

Subcutaneous injection most studied; oral delivery uniquely viable due to gastric juice origin and acid stability

Human RCTs

No completed, published randomized controlled trial in humans. Two trials registered on ClinicalTrials.gov as of 2024.

Mechanism of Action

How BPC-157 works

BPC-157 does not appear to act through a single receptor or a clean, one-pathway mechanism. Instead, the preclinical literature describes a compound that modulates several overlapping systems — vascular growth, nitric oxide signaling, growth factor expression, and dopaminergic pathways — in ways that converge on tissue repair and cytoprotection. What follows is the best current understanding of its signaling cascade, with the caveat that nearly all of this comes from rodent and in vitro data.

Administration & Absorption

BPC-157 is typically administered via subcutaneous injection near the target tissue, or orally. Unlike most peptides, BPC-157 demonstrates unusual stability in gastric acid — consistent with its origin as a fragment of a gastric juice protein. Following subcutaneous injection, the peptide enters interstitial fluid and local capillary networks. Oral administration delivers the peptide through the GI tract, where it appears to exert both local (mucosal) and systemic effects.

The peptide's acid stability is attributed to its proline-rich sequence (three consecutive prolines at positions 3–5), which confers resistance to pepsin and hydrochloric acid degradation. In vitro studies show BPC-157 remains structurally intact at pH 1.0 for over 24 hours (Sikiric et al., 2018). Pharmacokinetic data in rodents suggests rapid distribution from injection sites with a half-life estimated at 20–40 minutes, though formal human PK studies have not been conducted.

VEGFR2 Upregulation & Angiogenesis

A central finding across multiple rodent studies is that BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2), promoting the formation of new blood vessels (angiogenesis) at injury sites. This increased vascularization is believed to be one of the primary mechanisms behind its observed wound-healing and tendon-repair effects — injured tissue heals faster when blood supply is restored.

BPC-157 appears to activate VEGFR2 (KDR/Flk-1) signaling via increased VEGF-A expression, triggering the PI3K/Akt and MAPK/ERK downstream cascades. These pathways promote endothelial cell proliferation, migration, and tube formation. In a rat transected Achilles tendon model, VEGFR2 expression was significantly elevated at days 4 and 7 post-treatment (Chang et al., 2011). Notably, this pro-angiogenic activity is the basis of the theoretical cancer concern — in contexts where angiogenesis is pathological (e.g., tumor vascularization), enhanced VEGF signaling could hypothetically be harmful. No direct evidence of this has been observed, but the absence of evidence in the absence of human trials is not reassurance.

Nitric Oxide System Modulation

BPC-157 modulates the nitric oxide (NO) system, which regulates blood vessel dilation, inflammation, and tissue repair signaling. Rather than simply increasing or decreasing NO, BPC-157 appears to act as a modulator — counteracting both excessive NO (which drives inflammation) and insufficient NO (which impairs healing). This bidirectional activity has been observed in models of both hypertension and hypotension.

BPC-157 interacts with endothelial nitric oxide synthase (eNOS) and inducible NOS (iNOS) systems. In L-NAME-induced hypertension models (NOS blockade), BPC-157 restored blood pressure and NO levels. In L-arginine excess models (NO overproduction), it attenuated the effects. This suggests interaction with the NO-cGMP-PKG signaling pathway rather than direct NOS activation or inhibition. The mechanism may involve modulation of NOS phosphorylation state or cofactor availability (BH4), though the precise binding target has not been identified. This is a meaningful gap — the direct molecular target of BPC-157 remains unknown.

Growth Factor Expression

In injured tissue, BPC-157 has been shown to increase expression of several growth factors involved in repair: EGF (epidermal growth factor), FGF (fibroblast growth factor), and TGF-β. These are master regulators of cell proliferation, extracellular matrix deposition, and tissue remodeling. The net effect in animal models is accelerated wound closure, collagen deposition, and granulation tissue formation.

In rat skin wound models, BPC-157 increased EGF receptor (EGFR/ErbB1) phosphorylation and downstream STAT3 signaling, promoting keratinocyte migration and re-epithelialization. FGF-2 upregulation was observed in tendon fibroblast cultures, activating FGFR1 → PLCγ → PKC signaling. TGF-β1 elevation promotes collagen type I/III synthesis via Smad2/3 nuclear translocation. However, these growth factor changes may be secondary effects of improved vascularization rather than direct peptide-receptor interactions — this distinction has not been resolved experimentally.

Dopaminergic & GABAergic Modulation

A less widely discussed but well-documented effect is BPC-157's interaction with the central dopamine system. In rat models, it has counteracted the behavioral and neurochemical effects of both dopamine agonists and antagonists, suggesting a stabilizing or modulatory role. It has also shown effects on the GABAergic system, with anxiolytic-like behavior observed in elevated plus-maze tests.

BPC-157 counteracted amphetamine-induced locomotor hyperactivity and haloperidol-induced catalepsy in rodents (Sikiric et al., 2010), suggesting it does not simply agonize or antagonize D1/D2 receptors but modulates the system bidirectionally. It has been shown to affect dopamine transporter (DAT) expression and tyrosine hydroxylase (TH) activity in the striatum. GABA-A receptor interactions were suggested by diazepam-like anxiolytic effects that were partially blocked by flumazenil. The CNS effects remain poorly characterized mechanistically — no direct receptor binding studies have been published.

GI Cytoprotection

Consistent with its gastric juice origin, BPC-157 demonstrates strong cytoprotective effects on the gastrointestinal tract. It has protected against mucosal damage from NSAIDs, alcohol, and restraint stress in rodent models. It accelerates healing of gastric ulcers, intestinal anastomoses, and esophageal lesions. This is the most internally consistent body of evidence for BPC-157.

GI protection appears to involve multiple converging mechanisms: prostaglandin system modulation (maintaining PGE2 and PGI2 levels under NSAID challenge), mucosal blood flow preservation via NO-dependent vasodilation, and direct effects on intestinal tight junction proteins (claudin, occludin, ZO-1). In NSAID-induced gastric lesion models, BPC-157 maintained mucosal integrity even when cyclooxygenase was inhibited, suggesting prostaglandin-independent protective mechanisms as well. The GI evidence is the most extensive body of BPC-157 research, with over 30 published animal studies addressing various models of GI injury.

Delivery Routes

Administration methods

BPC-157 is somewhat unusual among peptides in that it has demonstrated activity through multiple routes of administration. Most peptides are degraded in the GI tract and require injection; BPC-157's gastric acid stability gives it a broader delivery profile — at least in animal models.

Subcutaneous Injection

Primary · Most Studied

Injected into the fatty tissue layer beneath the skin, typically near the area of injury. This is the most commonly studied route in animal models and the most commonly used route in off-label human use. Provides relatively rapid absorption into local tissues and systemic circulation. Standard insulin syringes (U-100) are used.

Oral Administration

Primary · Supported by GI Studies

Taken by mouth, typically in solution. Uniquely viable for BPC-157 due to its gastric acid stability. Oral administration is the primary route in GI-focused studies (ulcer healing, intestinal protection). Systemic bioavailability via oral route is less well characterized than local GI effects, and formal oral bioavailability studies in humans have not been published.

Intramuscular Injection

Experimental · Limited Data

Injected directly into muscle tissue. Used in some animal studies, particularly those examining muscle healing. Provides depot-like absorption. Less commonly used than subcutaneous in practice. No comparative bioavailability data exists between IM and SubQ routes for BPC-157 specifically.

Intraperitoneal (Research Only)

Research Context Only

Injection into the peritoneal cavity. Used extensively in rodent studies for systemic delivery but not a practical human administration route. Many of BPC-157's systemic effects (cardiovascular, neurological) were demonstrated via IP injection, which means the relevance of those findings to SubQ or oral use in humans is an open question.

Dosing Context

What the research used

There is no established human dosing protocol for BPC-157. What follows is a translation of doses used in published animal studies, presented for informational context. The commonly cited ranges in off-label use are derived from allometric scaling of rodent doses, which is an imprecise method that does not account for differences in metabolism, distribution, or receptor density between species.

Context	Dose	Route	Duration	Source
Tendon healing (rat)	10 µg/kg/day ~700 µg/day scaled to 70 kg human	IP / local	14–28 days	Chang et al., 2011
Gastric ulcer (rat)	10 µg/kg/day Also studied at 10 ng/kg (1000x lower)	Oral / IP	7–14 days	Sikiric et al., 1993
Intestinal anastomosis (rat)	10 ng – 10 µg/kg Dose-response curve across 3 orders of magnitude	IP	7–14 days	Seiwerth et al., 2014
Common off-label (human)	250–500 µg/day Not based on human trial data; derived from rodent allometric scaling	SubQ / Oral	4–8 weeks typical	No published source — practitioner consensus

Important Context

Allometric dose scaling from rats to humans is an approximation, not a validated dosing protocol. Rats have higher metabolic rates per kilogram than humans, and the FDA-recommended scaling factor (6.2x body surface area conversion) was designed for initial Phase 1 safety calculations, not therapeutic dosing. The "250–500 mcg/day" range commonly cited in practitioner communities has no published human efficacy or safety data supporting it.

Evidence Summary

Observed effects & concerns

The following reflects what has been observed in published research. Benefits are categorized by the strength of evidence behind them. Side effects include both observed adverse events and theoretical concerns raised by the mechanism of action.

Observed Benefits

Tendon & Ligament Healing

Accelerated healing of transected Achilles tendons, MCL injuries, and rotator cuff tears in multiple rat studies. Increased collagen organization and tensile strength at injury sites.

Evidence: Strong preclinical (5+ rodent studies) · No human data

Gastrointestinal Protection

Protected against NSAID-induced gastric lesions, ethanol damage, and stress ulcers. Accelerated healing of existing ulcers and surgical anastomoses. The most extensive evidence base for BPC-157.

Evidence: Strong preclinical (30+ studies) · No human data

Wound Healing & Skin Repair

Increased wound closure rate, collagen deposition, and angiogenesis at wound sites in rat incision and burn models.

Evidence: Moderate preclinical (3+ studies) · No human data

Neuroprotection

Reduced lesion volume and improved functional recovery in traumatic brain injury and peripheral nerve transection models. Counteracted neurotoxic effects of cuprizone and MPTP.

Evidence: Moderate preclinical · No human data

Anti-inflammatory Activity

Reduced inflammatory markers in adjuvant arthritis, colitis, and encephalomyelitis models. Effects attributed to NO modulation and prostaglandin pathway interactions.

Evidence: Moderate preclinical · No human data

Side Effects & Concerns

No Observed Acute Toxicity (Animal)

Rodent studies have not reported significant adverse effects at standard doses. LD50 has not been reached at tested dose ranges. However, the absence of adverse findings in short-duration rodent studies is a low bar — it does not constitute a human safety profile.

Context: No human safety data exists

Pro-Angiogenic Activity (Theoretical Risk)

BPC-157's VEGFR2 upregulation and pro-angiogenic effects are therapeutically beneficial for wound healing but raise a theoretical concern in individuals with active malignancies, where new blood vessel growth can feed tumor development. This risk has not been studied directly.

Risk level: Theoretical · Not studied in cancer models

Unknown Long-Term Effects

No study has examined chronic BPC-157 use beyond several weeks. Effects of sustained VEGF upregulation, growth factor modulation, and dopaminergic system interaction over months or years are completely unknown.

Risk level: Unknown · No chronic exposure data

Drug Interactions Not Characterized

BPC-157's interactions with the NO system, dopamine pathways, and prostaglandin synthesis suggest potential interactions with NSAIDs, blood pressure medications, antidepressants, and antipsychotics. None of these interactions have been formally studied.

Risk level: Unknown · No interaction studies

Gray Market Quality Concerns

BPC-157 is not available through regulated pharmaceutical channels. Products from research chemical suppliers vary in purity, sterility, and accurate labeling. Third-party testing of gray market BPC-157 has found contamination, under-dosing, and degradation products.

Risk level: Practical · Supply chain risk

Key Studies

What the research actually shows

Below are representative studies from the BPC-157 literature, selected to illustrate both the breadth of effects observed and the limitations that apply across the evidence base. Each entry includes what was studied, what was found, and what the study does not tell us.

Animal Model · Tendon Repair

BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts

Chang et al. · J Appl Physiol · 2011 · n = 60 rats

What They Studied

Achilles tendon transection in Sprague-Dawley rats. BPC-157 (10 µg/kg) administered intraperitoneally daily for 4, 7, or 14 days. Outcomes: tendon healing quality, collagen fiber organization, growth hormone receptor expression, VEGFR2 expression.

What They Found

BPC-157-treated tendons showed significantly better collagen organization, increased tensile strength, and elevated GH receptor and VEGFR2 expression compared to saline controls at all time points. The authors proposed that BPC-157 enhances tendon healing by promoting angiogenesis and growth factor signaling.

Study Limitations

Rodent model only — rat tendon biology differs from human tendon in collagen cross-linking, blood supply, and healing timelines. Sample size of 60 rats across 6 groups means n=10 per group. Intraperitoneal delivery does not reflect human subcutaneous use. No dose-response comparison. Single lab group (Zagreb) — the majority of BPC-157 research originates from a single research group led by Prof. Predrag Sikiric, which is an independence concern for the field.

View on PubMed

Animal Model · Gastric Protection

The effect of pentadecapeptide BPC 157 on gastric and duodenal lesions in rats

Sikiric et al. · J Physiol Paris · 1993 · Multiple cohorts

What They Studied

Multiple gastric and duodenal injury models in rats: ethanol-induced lesions, restraint stress ulcers, cysteamine-induced duodenal ulcers. BPC-157 administered at doses from 10 ng/kg to 10 µg/kg via oral and intraperitoneal routes.

What They Found

BPC-157 significantly reduced lesion area and severity across all models and both routes of administration. Effective at doses as low as 10 ng/kg (nanogram range), suggesting high potency. Oral and IP routes showed comparable efficacy, supporting GI-specific bioavailability for oral delivery.

Study Limitations

Rodent GI tract differs from human in acid production, mucosal turnover rate, and microbiome composition. These are acute injury prevention models, not chronic disease models. The dose range (10 ng/kg to 10 µg/kg) is exceptionally broad with similar efficacy claimed across 1,000-fold variation, which is pharmacologically unusual and warrants independent replication. Again, from the Zagreb research group.

View on PubMed

Animal Model · Neurobehavioral

Brain-gut axis and pentadecapeptide BPC 157: interaction with dopamine system

Sikiric et al. · World J Gastroenterol · 2017 · Review + original data

What They Studied

Comprehensive review with original data on BPC-157's interactions with the dopamine system. Tested against amphetamine, haloperidol, and various dopaminergic agents. Examined effects on dopamine turnover, receptor expression, and behavioral correlates in rats.

What They Found

BPC-157 counteracted both dopamine excess (amphetamine-induced hyperlocomotion) and dopamine blockade (haloperidol-induced catalepsy). Modified dopamine and serotonin turnover in the striatum, nucleus accumbens, and prefrontal cortex. Authors propose a "brain-gut axis" mediating mechanism.

Study Limitations

Animal behavioral models have poor translational validity for human psychiatric outcomes. The "bidirectional modulation" claim is interesting but mechanistically vague — no receptor binding data or direct molecular target identified. The "brain-gut axis" framing is speculative at this evidence level. Heterogeneous methodology across the compiled experiments makes it difficult to assess consistency. Same research group.

View on PubMed

What We Don't Know

Critical research gaps

For a compound with over 100 published papers, BPC-157 has remarkably large gaps in its evidence base. These are not minor omissions — they represent fundamental questions that would normally be answered before a compound enters widespread human use.

No Completed Human Randomized Controlled Trials

This is the most significant gap. As of 2025, no published RCT in humans exists for any indication. Two trials are registered on ClinicalTrials.gov (NCT05765006 for muscle injury, NCT06495112 for GI effects), but neither has published results. Every therapeutic claim about BPC-157 in humans is extrapolated from animal data.

No Human Pharmacokinetics or Bioavailability Data

Basic PK parameters — absorption rate, half-life, volume of distribution, clearance, oral bioavailability — have not been published for humans. Without this data, dosing in human use is essentially guesswork. We do not know what blood levels are achieved at commonly used doses, or how those levels compare to the tissue concentrations that produced effects in rodents.

Single Research Group Dominance

The overwhelming majority of BPC-157 research originates from a single group at the University of Zagreb led by Prof. Predrag Sikiric. While this does not invalidate their work, scientific credibility depends on independent replication. Very few of BPC-157's claimed effects have been replicated by independent laboratories. This is a structural weakness of the entire evidence base.

No Identified Direct Molecular Target

Despite extensive characterization of downstream effects, the direct binding target or receptor for BPC-157 has not been identified. We know what it appears to do — upregulate VEGFR2, modulate NO, affect dopamine turnover — but not how it initiates these cascades. This makes it difficult to predict interactions, contraindications, or off-target effects.

No Long-Term Safety Data

The longest published BPC-157 study durations are weeks, not months or years. For a compound that modulates angiogenesis, growth factor signaling, and neurotransmitter systems, the absence of chronic exposure data is a meaningful concern. We do not know what happens with sustained VEGF upregulation or prolonged dopamine system modulation.

No Cancer Safety Data

BPC-157's pro-angiogenic mechanism (VEGFR2 upregulation) is the same pathway that anti-cancer drugs like bevacizumab are designed to block. No study has examined BPC-157 in the context of active malignancy, tumor dormancy, or cancer predisposition. The theoretical risk is acknowledged in the literature but has never been directly tested.

References

Primary sources

1. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PubMed

2. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2018;24(18):2012-2032. PubMed

3. Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. J Physiol Paris. 1993;87(5):313-327. PubMed

4. Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. World J Gastroenterol. 2017;23(40):7175-7185. PubMed

5. Seiwerth S, Sikiric P, Grabarevic Z, et al. BPC 157's effect on healing. J Physiol Paris. 2014;108(2-3):128-135. PubMed

6. Sikiric P, Seiwerth S, Grabarevic Z, et al. Pentadecapeptide BPC 157 positively affects both non-steroidal anti-inflammatory agent-induced gastrointestinal lesions and adjuvant arthritis in rats. J Physiol Paris. 1997;91(3-5):113-122. PubMed

All BPC-157 on PubMed → ← Back to Research Library